STOCK TITAN
  1. Home
  2. Sec-filings
  3. TOI
  4. [Form 4] Oncology Institute, Inc. Insider Trading Activity

TOI Form 4 shows new director RSU awards and holdings update

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Oncology Institute, Inc. (TOI) director equity grants reported

A reporting person who serves as a director of Oncology Institute, Inc. disclosed the receipt of two grants of common stock in the form of restricted stock units on 11/20/2025. One grant covers 47,840 restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service through that date. The second grant covers 37,037 restricted stock units that were fully vested upon grant. Both entries show a price of $0, reflecting that these are equity awards rather than open-market purchases. After these grants, the reporting person beneficially owns 288,286 shares of common stock in direct ownership.

Positive

  • None.

Negative

  • None.
Insider Johnson Karen Marie
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 47,840 $0.00 --
Grant/Award Common Stock 37,037 $0.00 --
Holdings After Transaction: Common Stock — 251,249 shares (Direct)
Footnotes (1)
  1. Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date. Represents restricted stock units that were fully vested upon grant.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Johnson Karen Marie
(Last) (First) (Middle)
C/O THE ONCOLOGY INSTITUTE INC.
18000 STUDEBAKER RD, SUITE 800
(Street)
CERRITOS CA 90703
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/20/2025 A 47,840(1) A $0 251,249 D
Common Stock 11/20/2025 A 37,037(2) A $0 288,286 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date.
2. Represents restricted stock units that were fully vested upon grant.
/s/ Mark Hueppelsheuser, Attorney-in-Fact for Karen Marie Johnson 11/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction was reported for Oncology Institute, Inc. (TOI)?

A director of Oncology Institute, Inc. (TOI) reported receiving two grants of common stock in the form of restricted stock units on 11/20/2025.

How many Oncology Institute (TOI) shares were granted in the latest Form 4?

The director reported grants of 47,840 restricted stock units in one award and 37,037 restricted stock units in another award.

When do the new TOI restricted stock units vest?

The 47,840 restricted stock units vest in full on the Issuer’s 2026 annual stockholder meeting date, subject to continued service, while the 37,037 units were fully vested upon grant.

What price was paid for the Oncology Institute (TOI) equity awards?

Both restricted stock unit grants are shown at a price of $0, indicating they are equity awards and not open-market purchases.

How many Oncology Institute (TOI) shares does the reporting person now beneficially own?

Following the reported transactions, the director beneficially owns 288,286 shares of Oncology Institute common stock in direct ownership.

What is the reporting person’s relationship to Oncology Institute (TOI)?

The reporting person is identified as a Director of Oncology Institute, Inc. on the Form 4.